Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Abstract:

:In the present pharmacokinetic/pharmacodynamic (PK/PD) evaluation, cortisol, total lymphocytes, and lymphocyte subpopulations were monitored following single oral doses of two oral formulations of 3 mg budesonide (BUD) (Dosage Forms A and B) in order to assess the differential effects that BUD may have on cortisol suppression and the modulation of blood lymphocyte subtypes. On a single occasion, five subjects received one 3 mg capsule of Dosage Form A, four received three capsules of Dosage Form A (single dose of 9 mg), and five received three capsules of Dosage Form B (single dose of 9 mg). Placebo capsules were administered to six subjects in the study. Cortisol concentrations, total lymphocyte counts, and lymphocyte subpopulation counts for the CD3, CD4, CD8, CD19, and CD56/16 were fitted to an in direct PK/PD response model that described the effects of BUD on serum cortisol concentrations as well as the combined effects of BUD and cortisol on total lymphocytes and the CD3, CD4, CD8, CD19, and CD56/16 subtypes. Data were also analyzed using noncompartmental methods. The PK/PD model fitted the data with the exception of data for CD56/16. The IC(50) value for unbound BUD acting on total lymphocytes was 0.276 ng/ml while the IC(50) values for unbound BUD acting on lymphocyte subtypes ranged from 0.150 ng/ml for CD4 to 0.364 ng/ml for CD8. The IC(50) values for the effects of BUD on serum cortisol were lower (0.079 ng/ml). The results of PK/PD modeling and noncompartmental analysis indicate that BUD has a smaller effect on the CD8 subtype and larger effects on the CD4 and CD19 subtypes, relative to the effect on total lymphocytes, and that cortisol suppression, although not a direct immunological biomarker, may be a more sensitive marker for the systemic effect of corticosteroids.

authors

Stark JG,Werner S,Homrighausen S,Tang Y,Krieg M,Derendorf H,Moellmann H,Hochhaus G

doi

10.1007/s10928-006-9013-5

subject

Has Abstract

pub_date

2006-08-01 00:00:00

pages

441-59

issue

4

eissn

1567-567X

issn

1573-8744

journal_volume

33

pub_type

杂志文章
  • A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling.

    abstract::Development of novel therapies for bone diseases can benefit from mathematical models that predict drug effect on bone remodeling biomarkers. Therefore, a bone cycle model (BCM) was developed that takes into consideration the concept of the basic multicellular unit and the dynamic equilibrium of bone remodeling. The m...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9423-3

    authors: van Schaick E,Zheng J,Perez Ruixo JJ,Gieschke R,Jacqmin P

    更新日期:2015-08-01 00:00:00

  • Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

    abstract::In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-008-9098-0

    authors: Kjellsson MC,Zingmark PH,Jonsson EN,Karlsson MO

    更新日期:2008-10-01 00:00:00

  • Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

    abstract::This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among Japanese, Chinese, and Korean populations, following oral administration. We used a population PK modeling approach using data from a clinic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9556-7

    authors: Kaneko M,Aoyama T,Ishida Y,Miyamoto A,Saito Y,Tohkin M,Kawai S,Matsumoto Y

    更新日期:2018-04-01 00:00:00

  • Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

    abstract::The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9064-2

    authors: Hietala SF,Bhattarai A,Msellem M,Röshammar D,Ali AS,Strömberg J,Hombhanje FW,Kaneko A,Björkman A,Ashton M

    更新日期:2007-10-01 00:00:00

  • Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study.

    abstract::There are situations in drug development where one may wish to reduce the dimensionality and complexity of whole body physiologically based pharmacokinetic models. A technique for formal reduction of such models, based on global sensitivity analysis, is suggested. Using this approach mean and variance of tissue(s) and...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0004-8

    authors: Gueorguieva I,Nestorov IA,Rowland M

    更新日期:2006-02-01 00:00:00

  • Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

    abstract::The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The aim of the study was to develop PBPK model for amitriptyline given orally, ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9597-6

    authors: Tylutki Z,Mendyk A,Polak S

    更新日期:2018-10-01 00:00:00

  • Modelling overdispersion and Markovian features in count data.

    abstract::The number of counts (events) per unit of time is a discrete response variable that is generally analyzed with the Poisson distribution (PS) model. The PS model makes two assumptions: the mean number of counts (lambda) is assumed equal to the variance, and counts occurring in non-overlapping intervals are assumed inde...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10928-009-9131-y

    authors: Trocóniz IF,Plan EL,Miller R,Karlsson MO

    更新日期:2009-10-01 00:00:00

  • Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

    abstract::We used a previously developed physiologically based kinetic (PBK) model to analyze the effect of individual variations in metabolism and transport of cholesterol on pravastatin response. The PBK model is based on kinetic expressions for 21 reactions that interconnect eight different body cholesterol pools including p...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9369-x

    authors: van de Pas NC,Rullmann JA,Woutersen RA,van Ommen B,Rietjens IM,de Graaf AA

    更新日期:2014-08-01 00:00:00

  • A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

    abstract::Disease progression of type 2 diabetes (T2D) has received considerable attention, but little is known about the disease development of T2D. The purposes of this study were to identify disease development variables (DDV) for development of T2D and to compare corresponding models for disease development. All subjects in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9208-2

    authors: Lin CW,Warram JH,Veng-Pedersen P

    更新日期:2011-10-01 00:00:00

  • Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

    abstract::Cell-level kinetic models for therapeutically relevant processes increasingly benefit the early stages of drug development. Later stages of the drug development processes, however, rely on pharmacokinetic compartment models while cell-level dynamics are typically neglected. We here present a systematic approach to int...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9243-7

    authors: Krippendorff BF,Oyarzún DA,Huisinga W

    更新日期:2012-04-01 00:00:00

  • Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach.

    abstract::Neutropenia is a common side-effect of oncology drugs. We aimed to study the impact of exposure and dosing schedule on neutropenia to guide selection of dosing schedules that minimize neutropenia potential while maintaining the desired minimum concentration (Cmin) required for target engagement. Dose, frequency and PK...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09667-y

    authors: Guo Y,Haddish-Berhane N,Xie H,Ouellet D

    更新日期:2020-02-01 00:00:00

  • Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

    abstract::The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9586-9

    authors: Zang X,Kagan L

    更新日期:2018-08-01 00:00:00

  • When is a metric not a metric? Remarks on direct curve comparison in bioequivalence studies.

    abstract::The majority of measures proposed to date for direct curve comparison in bioequivalence studies were investigated. These measures have often been called metrics, but in most cases this was incorrect in the mathematical sense. It was demonstrated, with a set of counter-examples, that the axioms of a metric are fulfille...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9121-0

    authors: Jawień W

    更新日期:2009-06-01 00:00:00

  • A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.

    abstract::A hazard model of fracture was developed using individual patient data (IPD) from the NHANES (2005-2008) database and summary-level data from an aggregate dataset (AD). The AD was built by performing a comprehensive and systematic literature search of clinical studies published from 1995 to 2015, recording fracture ra...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9551-z

    authors: Eudy-Byrne RJ,Gillespie W,Riggs MM,Gastonguay MR

    更新日期:2017-12-01 00:00:00

  • Bioequivalence testing by statistical shape analysis.

    abstract::Bioequivalence testing has been traditionally centered in summary variables such as AUC, C (max) and t (max) which filter out the intrinsic information conveyed by discrete sequential concentration-time observations. Comparing entire concentration-time profiles between test and reference formulations for bioequivalenc...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9055-3

    authors: Pereira LM

    更新日期:2007-08-01 00:00:00

  • A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

    abstract::Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder. This paper proposes a mechanism-based approach to disease progression modeling of T2DM that aims to provide the ability to describe and quantify the effects of treatment ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9008-2

    authors: de Winter W,DeJongh J,Post T,Ploeger B,Urquhart R,Moules I,Eckland D,Danhof M

    更新日期:2006-06-01 00:00:00

  • Performance in population models for count data, part I: maximum likelihood approximations.

    abstract::There has been little evaluation of maximum likelihood approximation methods for non-linear mixed effects modelling of count data. The aim of this study was to explore the estimation accuracy of population parameters from six count models, using two different methods and programs. Simulations of 100 data sets were per...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9126-8

    authors: Plan EL,Maloney A,Trocóniz IF,Karlsson MO

    更新日期:2009-08-01 00:00:00

  • A compartmental model of hepatic disposition kinetics: 1. Model development and application to linear kinetics.

    abstract::The conventional convection-dispersion model is widely used to interrelate hepatic availability (F) and clearance (Cl) with the morphology and physiology of the liver and to predict effects such as changes in liver bloodflow on F and Cl. The extension of this model to include nonlinear kinetics and zonal heterogeneity...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1019703607647

    authors: Anissimov YG,Roberts MS

    更新日期:2002-04-01 00:00:00

  • Modeling cancer-immune responses to therapy.

    abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9386-9

    authors: dePillis LG,Eladdadi A,Radunskaya AE

    更新日期:2014-10-01 00:00:00

  • Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study.

    abstract::Altered expressions of the key enzymes in arachidonic acid (AA) metabolism, prostaglandin synthase 1 and 2 and cysteinyl leukotriene C(4) synthase, are of importance in understanding aspirin-induced asthma. We propose a mathematical model of AA metabolism and its interaction with non-steroidal anti-inflammatory drugs ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9192-6

    authors: Dobovišek A,Fajmut A,Brumen M

    更新日期:2011-04-01 00:00:00

  • Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

    abstract::The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011507100493

    authors: Hing JP,Woolfrey SG,Greenslade D,Wright PM

    更新日期:2001-04-01 00:00:00

  • Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.

    abstract::Minimal physiologically based pharmacokinetic (mPBPK) models provide a simple and sensible approach that incorporates physiological elements into pharmacokinetic (PK) analysis when only plasma data are available. With this modeling concept, a second-generation mPBPK model was further developed with specific accommodat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9374-0

    authors: Cao Y,Jusko WJ

    更新日期:2014-12-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract::Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9612-y

    authors: Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期:2019-02-01 00:00:00

  • Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.

    abstract::A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of PF-06804103 and T-DM1 was determined across a range of...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-020-09702-3

    authors: Betts A,Clark T,Jasper P,Tolsma J,van der Graaf PH,Graziani EI,Rosfjord E,Sung M,Ma D,Barletta F

    更新日期:2020-10-01 00:00:00

  • Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.

    abstract::A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10928-014-9356-2

    authors: Martinez JM,Khier S,Morita S,Rauch C,Fabre D

    更新日期:2014-04-01 00:00:00

  • Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

    abstract::Previously, we developed a feedback model to describe the tolerance and oscillatory rebound of non-esterified fatty acid (NEFA) plasma concentrations in male Sprague Dawley rats after intravenous infusions of nicotinic acid (NiAc). This study challenges that model, using the following regimens of intravenous and oral ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9325-1

    authors: Ahlström C,Peletier LA,Gabrielsson J

    更新日期:2013-08-01 00:00:00

  • Structural identifiability for mathematical pharmacology: models of myelosuppression.

    abstract::Structural identifiability is an often overlooked, but essential, prerequisite to the experiment design stage. The application of structural identifiability analysis to models of myelosuppression is used to demonstrate the importance of its considerations. It is shown that, under certain assumptions, these models are ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10928-018-9569-x

    authors: Evans ND,Cheung SYA,Yates JWT

    更新日期:2018-02-01 00:00:00

  • Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

    abstract::We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharm...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0048-9

    authors: Dokoumetzidis A,Aarons L

    更新日期:2005-08-01 00:00:00

  • Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

    abstract::The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the granulopoietic effects of Filgrastim in healthy volunteers was characterized via a population approach. Healthy male volunteers were enrolled into a four-way crossover clinical trial. Subjects received four single doses of Filgrastim (375 and 750 microgra...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011534529622

    authors: Wang B,Ludden TM,Cheung EN,Schwab GG,Roskos LK

    更新日期:2001-08-01 00:00:00

  • Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.

    abstract::Quantitative systems pharmacology (QSP) is a recent addition to the modeling and simulation toolbox for drug discovery and development and is based upon mathematical modeling of biophysical realistic biological processes in the disease area of interest. The combination of preclinical neurophysiology information with c...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9297-1

    authors: Geerts H,Spiros A,Roberts P,Carr R

    更新日期:2013-06-01 00:00:00